Industry Supported Sessions
The Journey of Interleukin-6 Blocking Therapy for autoimmune diseases
SYMPOSIUM IS ORGANISED AND SUPPORTED BY CHUGAI
Wednesday, May 20 | 15:30-17:30 | Hall 3 – Nikos Skalkotas
Chair: Takao Koike, Kazuhiko Yamamoto
15:30-15:40
Opening Remarks
15:40-16:10
New predictor for tocilizumab Treatment on rheumatoid arthritis
16:10-16:45
The Challenging of large vessel vasculitis treatment with tocilizumab
16:45-17:20
New Indication with IL-6 blocking therapy in autoimmune disease
Closing Remarks
Time to rethink the lung in the context of autoimmune rheumatic diseases
SYMPOSIUM IS ORGANISED AND SUPPORTED BY Boehringer Ingelheim
Thursday, May 21 | 12:45-13:45 | Hall 3 – Nikos Skalkotas
Chair: Yannick Allanore, France
12:45-12:50
Welcome and introduction
12:50–13:00
12:50–13:00
13:00–13:10
13:10–13:20
SSc-ILD: The archetype of lung involvement in autoimmune rheumatic diseases
New paradigms in the management of autoimmune rheumatic disease-related ILDs
Unraveling the pathogenesis of lung fibrosis in autoimmune rheumatic diseases
Non-SSc autoimmune rheumatic diseases: What to look for in the lung and why
Panel Discussion